Allergan snaps up Bonti
Irish pharma Allergan is buying privately-held, clinical-stage US biotech Bonti for access to its novel, fast-acting neurotoxin programmes for aesthetic and therapeutic applications.
Read More
Tag: Bonti
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
